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bstract
A simple, selective and precise method based on HPTLC has been developed for the simultaneous determination of aliskiren
nd hydrochlorothiazide in a fixed-dose tablet formulation and human plasma. The chromatography was performed on silica gel 60
F254 plates, with a mobile phase consisting of methanol–chloroform (6:4, v/v). Densitometric analysis of the analytes was carried
ut at 225 nm. Under optimized conditions, the Rf values were 0.26 ±  0.02 and 0.71 ±  0.02, and the resulting regression plots
ere linear (r2 ≥  0.9997) in the concentration ranges of 1.00–10.0 and 0.10–1.00 g band−1 for aliskiren and hydrochlorothiazide.
he limit of detection and limit of quantitation of the validated method were 0.206 and 0.624 g band−1 for aliskiren and 0.015
nd 0.046 g band−1 for hydrochlorothiazide, respectively. The % expected content of aliskiren and hydrochlorothiazide in the
ommercial tablet formulation was 99.2% and 101.3%, respectively. For spiked plasma sample preparation, the analytes and nebivolol
nternal standard were extracted from 500 L of plasma sample by solid-phase extraction on LiChrosep® DVB-HL cartridges. The
ean extraction recovery of aliskiren and hydrochlorothiazide from human plasma was 87.2% and 76.5%, respectively. In addition,
he stability of the analytes in plasma was established under different storage conditions.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hypertension is one of the major causes of many
cardiovascular diseases including stroke, myocardial
infarction and congestive heart failure. Thus, efficient
control and management of hypertension is essential
to minimize cardiovascular mortality and morbidity
[1–3]. Generally, the target blood pressure (BP) is belowalysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
behalf of Taibah University. This is an open access article under the
140/90 mmHg in hypertension patients. Reduction in
blood pressure significantly reduces the risk of organ
damage, vascular diseases and death. Currently, several
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aliskirenFig. 1. Chemical structures of the drugs (a) 
therapies are available to lower blood pressure, including
mono and combination therapy with -blockers, diuret-
ics, angiotensin-converting enzyme (ACE) inhibitors,
angiotensin II receptor blockers (ARB) and calcium
channel antagonists [4]. It has been observed that combi-
nation therapies using agents that have complementary
mechanisms of action as inhibitors of the renin-
angiotensin-aldosterone system (RAAS) are essential for
patients at high cardiovascular and renal risk.
Aliskiren (ALS, Fig. 1a) is the first orally active
non-peptide inhibitor that directly targets renin, and
it was approved by the US Food and Drug Adminis-
tration in March 2007 [3]. ALS inhibits RAAS at its
rate-limiting step by reducing the plasma renin activity
(PRA). ALS effectively controls blood pressure and is
generally well tolerated as either a monotherapy or in
combination with other antihypertensive drugs such as
hydrochlorothiazide (HCTZ, Fig. 1b), amlodipine and
valsartan [4,5]. HCTZ is a diuretic drug of the thiazide
class that inhibits active chloride reabsorption and thus
increases the excretion of sodium chloride and water.
It has been demonstrated that a fixed dose combination
of ALS with HTCZ in hypertensive patients provides
long-term efficacy and safety in blood pressure control
compared to monotherapy [5].
Several methods have been reported for the deter-
mination of ALS as an isolated sample or together
with other antihypertensive drugs in more compli-Please cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
cated matrices such as pharmaceutical formulations
and biological fluids. These methods have been based
on spectrophotometry [6–8], spectrofluorometry [9,10],
electrophoresis [11,12], liquid chromatography (LC), (b) hydrochlorothiazide and (c) nebivolol.
[8,13–21], LC–MS/MS [22–25] and UPLC–MS/MS
[26]. Similarly, a number of analytical methods have
been presented for the estimation of HCTZ as a single
analyte [27] and in the presence of different antihyperten-
sive agents [8,12,14,16,18,19,28–39] in pharmaceutical
preparations and biological matrices using spectropho-
tometry [29,32], capillary electrophoresis [28], HPTLC
[30,31], LC [33–35], UPLC [36], LC–MS/MS [37,38]
and UPLC–MS/MS [39]. However, there are no reports
for the simultaneous determination of aliskiren and
hydrochlorothiazide by HPTLC. This technique affords
parallel analyses of multiple samples in a single run
while using only small amounts of solvents, thereby
reducing the time and cost of analysis. Moreover, it pro-
vides accurate and precise results and is much easier to
carry out compared to HPLC or LC–MS. In the present
work, both drugs were analysed in their fixed dose
binary formulation (Tekturna HCT®, Novartis Pharma-
ceuticals) and in human plasma by HPTLC. The methods
developed were validated according to ICH guidelines
for linearity, sensitivity, selectivity, accuracy and preci-
sion, recovery, stability and robustness [40].
2.  Experimental
2.1.  Chemicals  and  materials
Reference standards of aliskiren hemifumarate (ALS,alysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
99.40%), hydrochlorothiazide (HCTZ, 99.52%) and
nebivolol (NBL, 99.8%, Fig. 1c) were purchased from
TLC Pharmachem Inc. (Ontario, Canada). HPLC grade
chloroform and methanol, acetic acid and ammonia
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olutions were purchased from E. Merck (Mumbai,
ndia). Aluminium-backed HPTLC pre-coated silica
el Plates 60 GF254 (20 cm ×  10 cm, 200 m layer
hickness) were procured from Merck KGaA (Darm-
tadt, Germany). Pharmaceutical formulation, Tekturna
CT® (300 mg aliskiren and 25 mg hydrochloroth-
azide) combination tablets were purchased from
ovartis Pharmaceuticals Corporation, East Hanover,
ew Jersey, USA. LiChrosep® DVB-HL (30 mg, 1 cc)
olid-phase extraction (SPE) cartridges were obtained
rom Merck Pvt. Ltd. (Mumbai, India). Blank human
lasma in K3EDTA was obtained from Supratech
icropath (Ahmedabad, India) and stored at −20 ◦C
ntil use.
.2.  HPTLC  equipment  and  conditions
The HPTLC system (CAMAG, Muttenz,
witzerland) consisted of a TLC Scanner III, Linomat
 auto-sprayer connected to a nitrogen cylinder and
late heater. The plates were washed with methanol
nd activated at 105 ◦C for 20 min prior to use. The
alibration standards, quality controls and samples of
harmaceutical formulation were applied to the plates
s 6-mm-wide bands with 6-mm spacing between each
and using a Hamilton microliter syringe and Linomat
 sample applicator. The sample application speed was
et at 10 mm s−1. The distance from the plate side edge
nd the bottom of the plate was 10 mm. After the plates
ere air dried, linear ascending chromatography was
arried out using methanol–chloroform (6:4, v/v) as the
obile phase in a 20 cm ×  10 cm twin-through glass
hamber (CAMAG), which was pre-saturated with
obile phase (for 15 min), at 25 ±  1 ◦C and 60 ±  5%
elative humidity. The development distance was 8.0 cm,
nd the development time was 20 min. Densitometric
canning was performed in the absorbance–reflectance
ode at 225 nm after scanning between 200 and 400 nm
sing a deuterium lamp. The slit dimensions were
 mm in length and 0.45 mm in width, with a scanning
ate of 20 mm s−1. Each track was scanned three
imes, and baseline correction was used. The winCATS
oftware version 1.4.2 (CAMAG) was used to control
he operating parameters during the entire experiment.
.3.  Preparation  of  standard  solutions,  calibration
tandards  and  quality  control  samplesPlease cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
Separate standard stock solutions of ALS
2.0 mg mL−1, free base form) and HCTZ
1.0 mg mL−1) were prepared by dissolving appropriate
mounts in methanol. PRESS
sity for Science xxx (2016) xxx–xxx 3
To prepare calibration plots, 1.0, 2.0, 3.0, 4.5, 6.0, 8.0
and 10.0 L of ALS working solution (1000 g mL−1)
and 1.0, 2.0, 3.0, 4.5, 6.0, 8.0 and 10.0 L of HCTZ work-
ing solution (100 g mL−1) were applied by co-spotting
on TLC plates to achieve a concentration in the ranges of
1.00–10.0 g band−1 for ALS and 0.10–1.00 g band−1
for HCTZ. The plates were developed and scanned
as described above. Similarly, quality control (QC)
samples were prepared at 2.50/0.25, 5.00/0.50 and
9.00/0.90 g band−1 for ALS/HCTZ.
To prepare spiked plasma calibration samples, a suit-
able aliquot from the respective stock solutions was
added to 0.5 mL of drug-free plasma (5% in blank
human plasma) to obtain concentrations in the ranges of
1.00–10.0 g band−1 for ALS and 0.10–1.00 g band−1
for HCTZ. Likewise, QC samples were prepared
at 2.50/0.25, 5.00/0.50 and 9.00/0.90 g band−1 for
ALS/HCTZ. In addition, a stock solution of nebivolol
(1.0 mg mL−1) was prepared in methanol and used as an
internal standard.
2.4.  Solid  phase  extraction  of  plasma  samples
NaOH (50 L, 0.01 N) was added to spiked plasma
samples (CSs and QCs), and the samples were briefly
vortexed for 15 s. The samples were then loaded on
LiChrosep® DVB-HL extraction cartridges, which were
preconditioned with 1.0 mL of methanol followed by
1.0 mL of 0.1% acetic acid in water. The samples were
washed with 2 ×  1.0 mL of 0.1% acetic acid in water. The
analytes and IS were eluted using 750 L of 2% ammo-
nia solution in methanol and collected in pre-labelled
vials. The samples were then evaporated to dryness under
a gentle stream of nitrogen at 30 ◦C. The dried samples
were reconstituted with 500 L of methanol and briefly
vortexed, and 10 L was used for band spotting on TLC
plates.
2.5.  Analysis  of  tablet  formulation
To determine the contents of ALS and HCTZ in
Tekturna HCT® tablet formulation (300 mg of aliskiren
and 25 mg of hydrochlorothiazide), 20 tablets were
weighed and ground to a fine powder. An amount equiv-
alent to 300 mg of ALS and 25 mg of HCTZ was
transferred into a 100-mL volumetric flask containing
50 mL of methanol, sonicated for 30 min and diluted
with additional methanol. After filtration, a working
−1alysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
solution having concentrations of 300 g mL ALS
and 25 g mL−1 HCTZ was prepared by diluting the
stock solution with methanol, and 10 L was applied
to the plates in six replicates. After chromatographic
ARTICLE IN PRESS+ModelJTUSCI-300; No. of Pages 10
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rothiazFig. 2. Zero-order spectra of aliskiren (25 g mL−1), hydrochlo
development, the peak areas of the bands were measured
at 225 nm, and the amount of each drug present in the
tablet was estimated from the regression equations.
3.  Results  and  discussion
3.1.  Method  development
To select the analytical wavelength for the quantifi-
cation of the drugs, standard solutions were prepared,
and their UV absorption spectra were acquired using a
spectrophotometer (Fig. 2). Upon assessment of their
overlain spectra, it was observed that the selected drugs
exhibited considerable absorbance at 225 nm, and hence,
this wavelength was selected for further analysis.
3.1.1. Optimization  of  chromatography
For chromatographic elution of analytes and IS, sev-
eral trials were carried out using toluene, n-hexane,
ethyl acetate, chloroform, dichloromethane, acetonitrile
and methanol as single mobile phase solvents and their
binary combinations. Initial experiments with single sol-
vents revealed negligible migration of NBL (retention
factor, Rf < 1.0) in toluene, n-hexane, ethyl acetate and
chloroform, while Rf was greater than 0.6 for ALS
and HCTZ with minimal resolution. In pure methanol
and acetonitrile, ALS and HCTZ had limited resolu-
tion (Rf ∼  3.5–4.0), while NBL gave a diffused spot and
migrated near the solvent front. Thus, optimization of
the mobile phase was performed by testing combina-Please cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
tions of these solvents. After several tests, it was found
that the methanol–chloroform solvent mixture provided
better resolution, with relatively lower diffusion and tail-
ing of the ALS band. Further experiments varied theiride (5 g mL−1) and nebivolol (IS, 5.0 g mL−1) in methanol.
ratio of the two solvents, and finally, the mobile phase
of methanol–chloroform (6:4, v/v) provided good reten-
tion, peak symmetries and adequate resolution between
the drugs. The Rf values under the optimized conditions
were 0.26 ±  0.02, 0.71 ±  0.03, and 0.56 ±  0.02 for ALS,
HCTZ and NBL, respectively (Figs. 3 and 4). Several
antihypertensive drugs, namely, amlodipine, ramipril,
candesartan, propranolol and nebivolol, were tested as
internal standards. The results showed that all drugs
except nebivolol were unsuitable either due to differ-
ent wavelength of absorption or limited chromatographic
resolution from the analytes.
3.1.2.  Optimization  of  extraction  process
To the best of our knowledge, there are no methods
for the simultaneous determination of ALS and HCTZ
in human plasma. Reported procedures for the estima-
tion of ALS either alone [22–24] or in combination with
other antihypertensive drugs [20,25] have used protein
precipitation (PP) with acetonitrile [20], liquid–liquid
extraction (LLE) with methyl tert-butyl ether [22] or
solid phase extraction (SPE) from human serum [23],
urine [25] or saliva [24]. Thus, to develop a simple
method, initial trials were performed using acetonitrile
as protein precipitant as reported by Mannemala and
Nagarajan [20]. Although the recovery for ALS was
quantitative (∼90%), the recovery of HCTZ was poor
(35–40%). Thus, further trials were conducted using SPE
with LiChrosep® DVB-HL extraction cartridges. Wash-
ing and elution steps were carefully optimized for precisealysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
recovery at all QC levels. Selective use of 0.1% acetic
acid in water for washing and 2% ammonia solution in
methanol for elution of analytes resulted in consistent
recovery for the analytes as well as the IS.
ARTICLE IN PRESS+ModelJTUSCI-300; No. of Pages 10
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.90 g band−1 (Rf 0.71 ± 0.02), (b) in tablet formulation (3.00 g ba
.2.  Method  validation
The developed method was validated for linear-
ty, accuracy (recovery) and precision, selectivity, limit
f detection (LOD) and limit of quantitation (LOQ),
obustness and stability as per ICH [40] and USFDA
41] guidelines. Linearity was determined by analy-
is of five linear curves in the concentration range of
.00–10.0 g band−1 for ALS and 0.10–1.00 g band−1
or HCTZ. The calibration plots for ALS and HCTZ
ere constructed by plotting the area under the peak
gainst analyte concentration and the regression equa-
ions were computed from these plots. The calibration
urves showed good linearity (r2 ≥  0.9997) over the con-
entration range for both of the analytes, as shown inPlease cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
able 1. For plasma samples, peak area ratio (analyte/IS)
ersus the concentration was plotted with r2 ≥  0.9998 for
LS and HCTZ.vely, (a) at concentrations of 9.00 g band−1 (Rf 0.26 ± 0.02) and
nd 0.25 g band−1).
The specificity of the method was assessed by
analysing the bands (in terms of Rf values) obtained
for the samples with those of standards, and the results
obtained were in good correlation. For the bioanalytical
method, the specificity in the measurement of the Rf val-
ues (six replicates) was in the range of 1.24–1.87%, with
the value expressed as % RSD. Similarly, the peak purity
of ALS and HCTZ was determined by comparing three
different positions of the chromatograms: peak start,
peak apex and peak end. The results found were in close
agreement for both of the analytes. Further, for plasma
samples, the selectivity was evaluated by analysing blank
plasma, plasma spiked with IS and together with the
analytes and IS, as shown in Fig. 4. The densitograms
showed no interference of plasma components at the Ralysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
f
values of the analytes or IS. At the same time, there
was no change in the Rf values in the plasma for both
of the analytes. The LOD and LOQ for the analytes
ARTICLE IN PRESS+ModelJTUSCI-300; No. of Pages 10
6 J.J. Pandya et al. / Journal of Taibah University for Science xxx (2016) xxx–xxx
lasma s
) and nFig. 4. HPTLC densitograms of (a) blank human plasma, (b) blank p
with aliskiren (5.00 g band−1), hydrochlorothiazide (0.50 g band−1
were calculated from the slope of the calibration lines
and the standard deviation of the intercept. The results
for neat solutions (aqueous samples) and in plasma are
summarized in Table 1.
To study the intra-day (repeatability) and inter-dayPlease cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
precision (intermediate precision) of the method, six
replicates of the mixed standards of ALS/HCTZ at
2.50/0.25, 5.00/0.50, 9.00/0.90 g band−1 were ana-
lysed on the same day and on three consecutive days,piked with nebivolol (1.00 g band−1) and (c) plasma sample spiked
ebivolol (1.00 g band−1).
respectively. The intra- and inter-day precision (% RSD)
for neat samples and in plasma was 0.46–1.75% and
0.75–5.31%, respectively, for both the analytes (Table 2).
The accuracy (recovery) for neat samples was deter-
mined by a standard addition technique. This wasalysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
performed at three levels: 80%, 100% and 120% of
pre-analysed samples. For plasma samples, the absolute
recovery was determined by comparing the peak areas
of freshly prepared (extracted) samples with unextracted
ARTICLE IN PRESS+ModelJTUSCI-300; No. of Pages 10
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Table 1
Linear regression and statistical data for aliskiren and hydrochlorothiazide.
Parameter Aliskiren Hydrochlorothiazide
Neat samples Plasma samples Neat samples Plasma samples
Wavelength (nm) 225 225
Concentration range (g band−1) 1.00–10.0 0.10–1.00
Rf values 0.26 ± 0.02 0.27 ± 0.01 0.71 ± 0.01 0.71 ± 0.02
Intercept 4.346 ± 2.077 3.805 ± 1.846 5.074 ± 1.904 4.273 ± 2.212
Slope of calibration line (S) 0.0333 ± 0.0018 0.0263 ± 0.0014 0.4133 ± 0.0560 0.3878 ± 0.0621
Correlation coefficient (r2) 0.9997 0.9998 0.9998 0.9999
LOD (g band−1) 3.3 s/S 0.206 0.232 0.015 0.019
LOQ (g band−1) 10 s/S 0.624 0.702 0.046 0.057
LOD: limit of detection; LOQ: limit of quantitation; s: standard deviation of the intercept.
L and−1.
U and−1.
s
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SLOQ: Aliskiren, 1.00 g band−1 and hydrochlorothiazide, 0.10 g b
LOQ: Aliskiren, 10.0 g band−1 and hydrochlorothiazide, 1.00 g b
tandard solutions having identical concentration at three
C levels [41]. The mean recovery of NBL was 89.3%.
he detailed results are presented in Table 3.
The stability of the stock solution and working solu-
ion of analytes and IS were checked for short-term
tability at room temperature and long-term stability at
◦C. The samples at room temperature were stable forPlease cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
 minimum period of 36 h, while the samples at 5 ◦C
ere stable for at least 30 days. Plasma sample stabil-
ty was evaluated by measuring the area ratio response
able 2
ntra- and inter-day accuracy and precision data for aliskiren and hydrochloro
onc. (g band−1) Intra-day (n = 6) 
Mean conc.
found ± SD
Precision (% RSD) Accuracy
eat samples
liskiren
2.50 2.51 ± 0.03 1.13 100.3 
5.00 5.02 ± 0.04 0.82 100.4 
9.00 8.98 ± 0.06 0.64 99.78 
ydrochlorothiazide
0.25 0.25 ± 0.004 1.75 98.8 
0.50 0.49 ± 0.002 0.46 98.4 
0.90 0.91 ± 0.008 0.87 101.5 
lasma samples
liskiren
2.50 2.48 ± 0.11 4.54 99.1 
5.00 4.95 ± 0.11 2.16 98.9 
9.00 8.89 ± 0.10 1.12 98.8 
ydrochlorothiazide
0.25 0.26 ± 0.010 3.87 104.4 
0.50 0.48 ± 0.005 1.09 96.2 
0.90 0.87 ± 0.010 1.17 96.5 
D: standard deviation, RSD: relative standard deviation; n: number of replic(analyte/IS) of samples against freshly prepared compar-
ison standards with identical concentrations at two QC
levels. Bench-top stability at 25 ±  1 ◦C, freeze–thaw sta-
bility, processed sample stability, dry extract stability at
5 ±  3 ◦C and long-term stability (at −70 ◦C) was per-
formed at both QC levels in six replicates. The results
indicate no significant change in the stability of the ana-alysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
lytes under any condition (Table 4).
Method robustness was tested under five differ-
ent conditions by changing the composition of mobile
thiazide.
Inter-day (n = 6)
 (%) Mean conc.
found ± SD
Precision (% RSD) Accuracy (%)
2.49 ± 0.02 0.75 99.6
4.99 ± 0.09 1.79 99.7
8.98 ± 0.09 0.98 99.7
0.25 ± 0.003 1.36 98.0
0.50 ± 0.003 0.55 100.8
0.89 ± 0.006 0.69 98.8
2.45 ± 0.06 2.47 97.8
4.93 ± 0.24 4.79 98.5
8.85 ± 0.47 5.31 98.3
0.24 ± 0.010 4.36 95.2
0.47 ± 0.004 0.75 93.4
0.85 ± 0.024 2.86 94.5
ates.
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Table 3
Recovery of drugs in dosage forms by standard addition method and in human plasma (n = 6).
Tablet formulation Tekturna HCT®
(300 mg ALS and 25 mg HCTZ)
Amount of
taken drug
(g band−1)
Amount of
pure drug
added
(g band−1)
Total amount
found
(g band−1)
(Mean ± SD)
Precision
(% RSD)
Recovery of
pure drug (%)
Standard addition method for dosage form
Aliskiren 3.00 2.40 5.41 ± 0.038 0.71 100.2
3.00 3.00 5.99 ± 0.052 0.87 99.7
3.00 3.60 6.61 ± 0.057 0.86 100.3
Hydrochlorothiazide 0.25 0.20 0.45 ± 0.006 1.24 98.5
0.25 0.25 0.49 ± 0.005 0.93 98.0
0.25 0.30 0.55 ± 0.004 0.77 98.3
QC level (g
band−1)
Mean conc.
found (g
band−1)
Precision (%
RSD)
Absolute
recovery (%)
Mean
recovery (%)
In spiked plasma samples
Aliskiren 2.50 2.16 ± 0.079 3.65 86.4 87.2
5.00 4.42 ± 0.211 4.78 88.4
9.00 7.82 ± 0.185 2.36 86.9
Hydrochlorothiazide 0.25 0.19 ± 0.010 5.17 74.8 76.5
0.50 0.39 ± 0.016 4.08 77.6
69 ± 0.
f replic0.90 0.
SD: standard deviation, RSD: relative standard deviation; n: number o
phase components (±0.2 mL for each), the volume
of methanol–chloroform (6.2:4.1, 5.8:3.9 and 6.3:4.2
(v/v)), the chamber saturation time (±3.0 min) and the
time from band application to chromatography and from
chromatography to band scanning (±10.0 min). The
results shown in Table 5 establish that alteration of thePlease cite this article in press as: J.J. Pandya, et al. Simultaneous an
preparations and spiked human plasma by HPTLC, J. Taibah Univ.
analytical conditions does not affect the performance
of the method significantly, as evident from the pre-
cision values in the measurement of peak area of the
Table 4
Stability data of aliskiren and hydrochlorothiazide under different conditions 
Storage conditions Aliskiren 
Nominal conc.
(g band−1)
Mean stability
sample
(g band−1) ± SD
Bench top stability at room
temperature, 12 h
2.50 2.63 ± 0.04 
9.00 9.18 ± 0.09 
Freeze & thaw stability at
−70 ◦C, three cycles
2.50 2.41 ± 0.04 −
9.00 8.64 ± 0.08 −
Processed sample stability at
room temperature, 12 h
2.50 2.40 ± 0.04 −
9.00 8.82 ± 0.08 −
Dry extract stability At
5 ± 3 ◦C, 12 h
2.50 2.55 ± 0.04 
9.00 9.32 ± 0.10 
Long term stability at −70 ◦C,
60 days
2.50 2.59 ± 0.03 
9.00 8.84 ± 0.09 −
SD: standard deviation, n: number of replicates %Change = Mean stability sampleMean com025 3.57 77.0
ates.
analytes. This confirms the robustness of the developed
method. Finally, the method was used to analyse a com-
mercially available tablet formulation, Tekturna HCT®
(300 mg aliskiren and 25 mg hydrochlorothiazide). The
average assay % (±  SD) for ALS was 99.6 ±  0.74% and
100.2 ±  0.53% for HCTZ, which proves that the methodalysis of aliskiren and hydrochlorothiazide in pharmaceutical
 Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.001
is suitable for the analysis of ALS and HCTZ from
the pharmaceutical formulation without any interference
from the excipients.
(n = 6).
Hydrochlorothiazide
% Change Nominal conc.
(g band−1)
Mean stability
sample
(g band−1) ± SD
% Change
5.36 0.25 0.24 ± 0.007 −2.80
2.76 0.90 0.92 ± 0.017 2.22
3.74 0.25 0.24 ± 0.009 −4.01
3.97 0.90 0.92 ± 0.015 1.77
4.07 0.25 0.26 ± 0.007 3.61
2.06 0.90 0.86 ± 0.027 −5.11
1.84 0.25 0.26 ± 0.006 2.80
3.52 0.90 0.87 ± 0.019 −3.13
3.72 0.25 0.24 ± 0.010 −4.81
1.74 0.90 0.91 ± 0.010 0.78
s–Mean comparison samples
parison samples × 100.
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Table 5
Results for robustness of the method (n = 5).
Condition Aliskiren (5.0 g band−1) Hydrochlorothiazide (0.50 g band−1)
Mean peak
area
Standard
deviation of
peak area
RSD (%) Mean peak
area
Standard
deviation of
peak area
RSD (%)
Mobile phase composition (±0.2 mL) 3176 36.86 1.16 5845 61.37 1.05
Mobile phase volume (±5.0%) 3178 27.65 0.87 5844 57.86 0.99
Chamber saturation time (±3.0 min) 3178 33.37 1.05 5843 60.78 1.04
Time from spotting to chromatography (10.0 min) 3177 39.08 1.23 5844 50.26 0.86
T 6.54 
R
4
d
t
I
t
i
t
a
m
t
p
a
c
C
A
o
L
e
R
[
[
[
[
[ime from chromatography to scanning (10.0 min) 3176 3
SD: relative standard deviation.
.  Conclusion
A selective and robust HPTLC method has been
eveloped for the determination of ALS and HCTZ in
ablet formulation and spiked human plasma following
CH guidelines. This is possibly the first method for
he simultaneous estimation of this drug combination
n human plasma by any technique. Further, the sta-
istical analysis proves that the method is suitable for
nalysing ALS and HCTZ in their pure form and in phar-
aceutical preparations without any interference from
he excipients. The validation data suggest that the pro-
osed densitometric method is reproducible, accurate
nd precise, and it can be readily applied for pharma-
okinetic/bioequivalence studies.
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